Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer

Shinkichi Takamori, Gouji Toyokawa, Isamu Okamoto, Kazuki Takada, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Masakazu Katsura, Nobutaka Mukae, Fumihiro Shoji, Tatsuro Okamoto, Yoshinao Oda, Toru Iwaki, Koji Iihara, Yoichi Nakanishi, Yoshihiko Maehara

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.

Original languageEnglish
Pages (from-to)4223-4228
Number of pages6
JournalAnticancer research
Volume37
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Death
Ligands
Radiotherapy
Brain
Jejunum
Adrenal Glands
Spleen
Biopsy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer. / Takamori, Shinkichi; Toyokawa, Gouji; Okamoto, Isamu; Takada, Kazuki; Kozuma, Yuka; Matsubara, Taichi; Haratake, Naoki; Akamine, Takaki; Katsura, Masakazu; Mukae, Nobutaka; Shoji, Fumihiro; Okamoto, Tatsuro; Oda, Yoshinao; Iwaki, Toru; Iihara, Koji; Nakanishi, Yoichi; Maehara, Yoshihiko.

In: Anticancer research, Vol. 37, No. 8, 01.08.2017, p. 4223-4228.

Research output: Contribution to journalArticle

Takamori, S, Toyokawa, G, Okamoto, I, Takada, K, Kozuma, Y, Matsubara, T, Haratake, N, Akamine, T, Katsura, M, Mukae, N, Shoji, F, Okamoto, T, Oda, Y, Iwaki, T, Iihara, K, Nakanishi, Y & Maehara, Y 2017, 'Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer', Anticancer research, vol. 37, no. 8, pp. 4223-4228. https://doi.org/10.21873/anticanres.11813
Takamori, Shinkichi ; Toyokawa, Gouji ; Okamoto, Isamu ; Takada, Kazuki ; Kozuma, Yuka ; Matsubara, Taichi ; Haratake, Naoki ; Akamine, Takaki ; Katsura, Masakazu ; Mukae, Nobutaka ; Shoji, Fumihiro ; Okamoto, Tatsuro ; Oda, Yoshinao ; Iwaki, Toru ; Iihara, Koji ; Nakanishi, Yoichi ; Maehara, Yoshihiko. / Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer. In: Anticancer research. 2017 ; Vol. 37, No. 8. pp. 4223-4228.
@article{4a9eea21fcdc42419339304997fe7d2e,
title = "Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer",
abstract = "Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being 5{\%} were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14{\%}) and 2 (10{\%}) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.",
author = "Shinkichi Takamori and Gouji Toyokawa and Isamu Okamoto and Kazuki Takada and Yuka Kozuma and Taichi Matsubara and Naoki Haratake and Takaki Akamine and Masakazu Katsura and Nobutaka Mukae and Fumihiro Shoji and Tatsuro Okamoto and Yoshinao Oda and Toru Iwaki and Koji Iihara and Yoichi Nakanishi and Yoshihiko Maehara",
year = "2017",
month = "8",
day = "1",
doi = "10.21873/anticanres.11813",
language = "English",
volume = "37",
pages = "4223--4228",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer

AU - Takamori, Shinkichi

AU - Toyokawa, Gouji

AU - Okamoto, Isamu

AU - Takada, Kazuki

AU - Kozuma, Yuka

AU - Matsubara, Taichi

AU - Haratake, Naoki

AU - Akamine, Takaki

AU - Katsura, Masakazu

AU - Mukae, Nobutaka

AU - Shoji, Fumihiro

AU - Okamoto, Tatsuro

AU - Oda, Yoshinao

AU - Iwaki, Toru

AU - Iihara, Koji

AU - Nakanishi, Yoichi

AU - Maehara, Yoshihiko

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.

AB - Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85026243150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026243150&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11813

DO - 10.21873/anticanres.11813

M3 - Article

VL - 37

SP - 4223

EP - 4228

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -